Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Niacin and butyrate: nutraceuticals targeting dysbiosis and intestinal permeability in Parkinsons disease
confirmed that overexpressed SLC1A3 in gastric cancer activates the PI3K/AKT pathway, upregulates the expression levels of Glucose transporter 1 (GLUT1), Hexokinase 2 (HK2), and Lactate dehydrogenase A (LDHA), and promotes the growth of gastric cancer, while treatment with the PI3K/AKT inhibitor LY294002 could inhibit the growth-promoting effect of SLC1A3 overexpression on gastric cancer
Reducing the intake of foods rich in carnitine and choline seems to be highly consistent with the low-salt, low-fat diet advocated for cardiovascular disease
JPM 11, 1141
S2CID 236219189
US$ 27.63
US$ 22.32
US$ 23.64
US$ 20.11
US$ 21.89
